Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SGK1 | O00141 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.40 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.40 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878244 | 0.92 | SGK1 (0.46) | MEN1KMT2ASGK1PGRSLC40A1 | |
| SCHEMBL4876133 | 0.87 | BRAF (0.46) | SLC22A12MEN1KMT2ASGK1PIK3CA | |
| SCHEMBL4876037 | 0.84 | SLC22A12 (0.62) | SLC22A12PIK3CAPTPN2PTPN1PTPN5 | |
| SCHEMBL4875769 | 0.84 | HTR6 (0.53) | MEN1KMT2APIK3CA | |
| SCHEMBL4875699 | 0.81 | ALDH1A1 (0.49) | MEN1KMT2APIK3CAPTPN2PTPN1 | |
| SCHEMBL4878331 | 0.81 | KIT (0.46) | SGK1PIK3CA | |
| SCHEMBL4879656 | 0.79 | L3MBTL1 (0.47) | MEN1KMT2A | |
| SCHEMBL4875782 | 0.78 | CA12 (0.48) | KMT2APIK3CAPTPN2PTPN1PTPN5 | |
| SCHEMBL4879404 | 0.75 | TSHR (0.52) | KMT2APTPN2PTPN1PTPN5PGR | |
| SCHEMBL4876461 | 0.75 | TSHR (0.45) | MEN1KMT2APIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1846399-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082371-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | TIE1, TEK, KDR | SLC22A12 2993/4885MEN1 1907/4885KMT2A 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.